Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Continuing our dealmaking series, we explore one of the initial stages—finding a suitable partner—and provide advice on attracting and selecting the right match for your company and products.
Early-stage developments are attracting investment and driving dealmaking within the challenging neuroscience field, particularly for pain and Alzheimer’s disease, as the industry aims to move past the many late-stage clinical failures in recent years.
In the wake of the surge of interest in bispecific antibodies for cancer therapy, bispecifics are now being pursued in a wide range of other disease areas, driving further dealmaking.
Against the backdrop of a very deep and broad pipeline, the next breakthroughs in the immuno-oncology space will hinge on leveraging partnerships to improve existing therapies and to develop new strategies.
As a result of the recent landmark gene therapy and chimeric antigen receptor T cell approvals, momentum is building in the field of regenerative medicine. Increased funding and regulatory support has brought confidence to developers that are now bringing a new generation of concepts to the clinic.
Digital solutions, artificial intelligence, drug delivery, progress in precision medicine and immune-oncology – As always NLSDays Super Sessions tackle the big questions
The market for drugs and vaccines to combat infectious diseases is expanding overall, but with wide variation in sales among its segments. This article analyzes the products, trends and dealmaking underlying these changes.
Fibrosis-related diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis, have generated a wave of deal and funding activity over recent years. Here, we highlight a selection of these deals.
Inadequate or unsuitable intellectual property (IP) protection could allow competitors to more easily launch a competing product, jeopardizing the opportunity for meaningful return on investment and consequently potential dealmaking. This feature discusses key factors for biotechnology companies to consider in creating IP strategies to support value.
Are you a scientist-entrepreneur with an outstanding start-up company based on scientific research? Or a university or research institution looking to showcase your most promising academic spin‑off?
Although dealmaking in the medtech industry slowed in 2017, political developments and innovations in areas such as digital health technologies could fuel greater activity in 2018.
In a week that was relatively quiet for dealmaking compared to many others this year, there were still two high-value deals in the CNS space, which continues to generate deals and funding despite recent clinical failures in the area.
Oncology is currently the leading area for dealmaking, driven by immuno-oncology, which accounted for 32 of the 35 multibillion-dollar oncology licensing deals of the last five years. In this feature, authors at Clarivate Analytics explore the recent trends in oncology deals.
Whilst many of the world’s infectious diseases are managed well due to advances in scientific research, drug-resistant bacterial infections and emerging pathogenic viruses such as Zika still continue to pose major and pressing threats to public health.
